Loading clinical trials...
Loading clinical trials...
Evaluation of Lipoic Acid as a Treatment for Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD): Phase I- Tolerability Study and Phase II Pilot- Determine the Effects of ALA on the Progression of Geographic Atrophy (GA) in Patients With Age-related Macular Degeneration (AMD).
Conditions
Interventions
alpha lipoic acid
Placebo
Locations
5
United States
University of Iowa Hospitals and Clinics, Department of Ophthalmology & Visual Sciences
Iowa City, Iowa, United States
NJ Retina
Teaneck, New Jersey, United States
Oregon Regina. LLP
Eugene, Oregon, United States
Retina Northwest, P.C.
Portland, Oregon, United States
Scheie Eye Institute of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
Start Date
November 1, 2015
Primary Completion Date
February 15, 2019
Completion Date
March 1, 2019
Last Updated
August 6, 2020
NCT05913063
NCT06990269
NCT06970665
NCT07160179
NCT06557460
NCT05562947
Lead Sponsor
University of Pennsylvania
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions